The pharmaceutical company will establish a production facility in Odense to accommodate multiple product types within the ...

Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

The 40,000-square-metre (430,000-square-feet) production facility and warehouse in Odense "marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new ...

Novo Nordisk unveils a $1.2 billion production facility in Denmark and finalizes Catalent acquisition, with financial and ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Novo Nordisk has announced an investment of 8.5 billion Danish kroner, or approximately $1.2bn, to establish a new rare disease production facility in Odense, Denmark. Construction on the new site, ...

Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged ...

Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was investing 8.5 billion kroner ($1.2 billion) to build a new factory in ...

The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing ... A slight negative effect on operating profit growth and a reduction in free ...